Patent: 9,808,449
✉ Email this page to a colleague
Summary for Patent: 9,808,449
Title: | S1P modulating agents |
Abstract: | Compounds of formula (I) or (II) can modulate the activity of S1P receptors. |
Inventor(s): | Thomas; Jermaine (Chelsea, MA), Mi; Sha (Belmont, MA), Lin; Edward Yin-Shiang (Ashland, MA), Zheng; Guo Zhu (Lexington, MA), Ma; Bin (Arlington, MA), Caldwell; Richard D. (Melrose, MA), Guckian; Kevin (Northborough, MA), Kumaravel; Gnanasambandam (Lexington, MA) |
Assignee: | BIOGEN MA INC. (Cambridge, MA) |
Application Number: | 14/757,822 |
Patent Claims: | see list of patent claims |
Details for Patent 9,808,449
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Biogen Inc. | AVONEX | interferon beta-1a | For Injection | 103628 | 05/17/1996 | ⤷ Try a Trial | 2031-02-07 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 05/28/2003 | ⤷ Try a Trial | 2031-02-07 |
Biogen Inc. | AVONEX | interferon beta-1a | Injection | 103628 | 02/27/2012 | ⤷ Try a Trial | 2031-02-07 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 03/07/2002 | ⤷ Try a Trial | 2031-02-07 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/17/2004 | ⤷ Try a Trial | 2031-02-07 |
Emd Serono, Inc. | REBIF | interferon beta-1a | Injection | 103780 | 12/21/2012 | ⤷ Try a Trial | 2031-02-07 |
Biogen Inc. | TYSABRI | natalizumab | Injection | 125104 | 11/23/2004 | ⤷ Try a Trial | 2031-02-07 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |